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Abstract
We describe oligonucleotides (ODNs) that inhibit hepatitis C virus (HCV) RNA synthesis in vitro. From a series of 13 ODNs
complementary to the 3-end of the minus-strand HCV RNA, only 4 inhibited RNA synthesis with IC50 values lower than 1 M. The
inhibition was sequence-specific, since no effect was observed when the ODNs were used with a noncomplementary template. The
introduction of a 2-O-methyl modification increased the inhibitor activity 11-fold (IC50  50 nM) in just 1 (ODN7) of the 4 inhibitory
ODNs. ODNs did not inhibit RNA synthesis by interfering with the elongation process as no short RNAs products were detected. We also
show that ODN7 did not prevent binding of NS5B to the template or cause polymerase trapping by the duplex RNA/ODN. Our data
demonstrate that ODN7 inhibits the initiation process, most probably by modifying structural features present at the 3-end of the
minus-strand RNA.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Hepatitis C virus (HCV)1 is the major causative agent of
sporadic and posttransfusion non-A non-B hepatitis. HCV
infection often progresses to chronic hepatitis, cirrhosis, and
hepatocellular carcinoma (Choo et al., 1989; Saito et al.,
1990). To date, the most effective treatment has been a
combination of interferon- and the nucleoside analog riba-
virin. Nevertheless, this treatment leads to a decrease in
viral load in only 40% of infected patients. Strategies to
improve the efficiency of this treatment, including the use of
a pegylated derivative of interferon-, lead to a sustained
virological response in about 50% of patients (Manns et al.,
2001). A more efficient antiviral therapy is therefore ur-
gently required.
HCV is a member of the Flaviviridae family. It is an
enveloped virus with a single-stranded positive-sense RNA
genome that contains a single long open reading frame
(ORF) translated as a polyprotein of about 3010 amino acids
(Clarke, 1997). The polyprotein precursor is cleaved by
cellular and viral proteinases to yield the core (C), envelope
(E1 and E2), the p7 protein, and the nonstructural proteins
(NS2 to NS5B). The ORF is flanked by two highly con-
served nontranslated regions (UTR). The 5 UTR contains
sequences necessary for the replication and the translation
of the ORF (Wang et al., 1993; Rijnbrand et al., 1995;
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Friebe et al., 2001; Kim et al., 2002). The 3-UTR is com-
posed of a short variable region, a polypyrimidine tract
(poly U-UC) of variable length and a highly conserved
98-nucleotide segment (3X). The two latter domains are
essential for viral infectivity in vivo (Yanagi et al., 1999)
and RNA replication of HCV replicons in Huh7 cells
(Friebe et al., 2002, Yi et al., 2003).
The nonstructural protein NS5B has an RNA-dependent
RNA polymerase (RdRp) activity (Berhens et al., 1996;
Lohmann et al., 1997) and is the core enzyme that ensures
the replication of the RNA viral genome (Lohmann et al.,
1999). In a first step, the NS5B synthesizes a minus-strand
RNA that serves as template for the synthesis of new plus-
strand RNA molecules. As RNA synthesis is a crucial step
in the viral replication cycle, the search for compounds able
to interfere specifically with HCV RNA replication might
lead to the development of inhibitors able to stop or to slow
down viral proliferation in infected patients. Two strategies
may be used for this; either directly affecting the NS5B
activity with specific enzyme inhibitors or preventing RNA
synthesis with antisense oligonucleotides (ODNs).
Several nucleoside and nonnucleoside inhibitors of viral
polymerases have been assayed on HCV NS5B activity.
These compounds do not inhibit the polymerase activity, or
inhibition takes place at doses higher than 100 M (Loh-
mann et al., 1998; Ferrari et al., 1999; Ishii et al., 1999;
Alaoui-Lsmaili et al., 2000). Recently, ViroPharma released
a patent describing methylene-substituted rhodamine and
methylene-substituted barbituric acid derivatives that inhibit
HCV NS5B with IC50 values of 20 nM and 0.1–30 M,
respectively. The IRBM (Istituto di Ricerche di Biologia
Molecolare) has also disclosed a series of -aryl-,-dike-
toacids with IC50 values of 50 nM. Heterocyclic compounds
and nonnucleoside analogue inhibitors were also shown to
specifically inhibit RNA synthesis catalyzed by the purified
polymerase in the Huh7 cell-based replicon system (Dhanak
et al., 2002; Wang et al., 2002). Very recently, Biroccio et
al. (2002) isolated an RNA aptamer with high affinity for
HCV NS5B that inhibited enzyme activity in vitro but its
inhibitory activity on RNA replication has not been evalu-
ated ex vivo.
The second approach to inhibit RNA synthesis directed
by HCV NS5B is the development of antisense oligode-
oxynucleotides (ODNs) complementary to the plus- or mi-
nus-strands of the HCV RNA. The antisense strategy has
been widely used to inhibit expression of many cellular and
viral genes. The efficiency of such molecules has been
improved by introducing chemical modifications that in-
crease their nuclease resistance, affinity, and cellular uptake
(Cook, 1991; Crooke and Bennett, 1996; Boulme´ et al.,
1998; Freund et al., 2001).
When different antisense ODNs were used to interfere
with the HCV IRES and the 5-end of the core protein
coding sequence, specific inhibition of in vitro and ex vivo
translation of hepatitis C viral proteins was found (Wakita
and Wands, 1994; Alt et al., 1995; Hanecak et al., 1996;
Vidalin et al., 1996; Wakita et al., 1999). A 20-mer phos-
phorothioate antisense complementary to the initiation re-
gion of HCV translation (Di Bisceglie, 1999) is undergoing
clinical trials in patients infected with HCV.
The initiation step of plus- and minus-strand RNA syn-
thesis seems an attractive and still unexploited target for
antisense inhibitors. The HCV RdRp is able to initiate
primer-independent RNA synthesis on RNA templates (Luo
et al., 2000; Sun et al., 2000; Zhong et al., 2000). A -hair-
pin protruding toward the active site of the enzyme plays an
important role in positioning the 3-end of the viral genome
for correct initiation of replication (Hong et al., 2001), but
the exact mechanism of this process is unknown. It has been
reported that cis-acting sequences located at the 3-end of
both plus- and minus-strand RNAs allow initiation of RNA
synthesis of both polarities. Such elements have been iden-
tified at the end of the HCV genome both in vitro with a
recombinant enzyme and using the HCV replicon in cell
cultures (Oh et al., 1999, 2000; Friebe et al., 2001; Kim et
al., 2002; Friebe et al., 2002; Yi et al, 2003). In the 3 UTR,
the 3X, the poly (U-UC) tract and the variable region were
found to contribute to efficient replication in hepatoma cells
transfected by HCV subgenomic replicon but with different
efficiency. The 3X and the poly (U-UC) tract are absolutely
required, whereas the variable region only enhances the
replication level. This latter domain was shown to be dis-
pensable for HCV in vivo infectivity in chimpanzee (Yanagi
et al., 1999). Oh et al. (1999) showed that a recombinant
NS5B can use 341-or 239-nt-long RNA fragments derived
from the 3-terminus of the () strand HCV RNA as tem-
plate, but did not use segments of 44, 84, and 122 nt. By
generating a series of HCV replicons with deletions in the 5
UTR, Friebe et al. (2001) and Kim et al. (2002) showed that
the first 125 nt of the HCV genome are necessary and
sufficient for RNA replication and that almost all the 5
UTR is required for efficient RNA replication. All these
results suggested that large domains are required for initia-
tion of RNA from the 3 ends of () and () minus strand
of HCV RNA. Further studies are needed to identify the
sequences and/or the structures involved in the formation of
an active initiation complex.
In this study, we describe a series of antisense ODNs
complementary to the 3 terminal region of the minus-
strand viral RNA able to inhibit the in vitro synthesis of
the plus-strand RNA catalyzed by a recombinant HCV
NS5B. We show that a chemically modified antisense
ODN (2-O-methyl or phosphoramidate) targeting the
sequence localized between nt 85 and 103 from the 3-
end of the minus-strand RNA is able to inhibit in vitro
RNA synthesis with an IC50 of 50 and 30 nM, respec-
tively. Our data also indicate that this ODN inhibits an
early step of the RNA synthesis initiated at the 3-termi-
nus of the HCV minus-strand RNA.
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Results
Inhibition of in vitro RNA synthesis by phosphodiester
ODNs
The replication of the genome of the plus-strand RNA
viruses comprises two steps: the synthesis of a minus-strand
RNA using the plus-strand viral RNA genome as template
and the subsequent synthesis of the plus-strand viral RNA
using the newly synthesized minus-strand RNA as template.
The presence of 10-fold more plus-strand RNA compared to
minus-strand RNA in liver tissue has been demonstrated
(Craggs et al., 2001). On the other hand, we have previously
shown that the 3-end of the HCV minus-strand RNA is
very efficiently replicated by the purified HCV NS5B in
vitro (Reigadas et al., 2001). Altogether these results sug-
gest that the 3-end of the HCV minus-strand RNA contains
sequences and/or structures allowing a high level of RNA
synthesis by NS5B. We thus decided to develop antisense
ODNs targeted to the 3-end of the minus-strand viral RNA
in order to specifically inhibit the in vitro RNA synthesis by
the recombinant HCV NS5B. The target sequences were
chosen from the secondary structure of this region deter-
mined by Schuster et al. (2002) and Smith et al. (2002).
Thirteen antisense ODNs were synthesized and their inhib-
itory activity on RNA synthesis was evaluated using a
341-nt fragment of the 3-end of the minus-strand RNA,
called ()IRES RNA. As shown in Table 1, among the 13
ODNs tested, only 8 inhibited RNA synthesis, with different
efficiencies. Thus, ODNs 5, 8, 10, and 13 inhibited RNA
synthesis with IC50 values higher than 1 M, whereas
ODNs 3, 7, 9, and 12 gave IC50 values 1 M.
Table 1
Effect of antisense ODNs complementary to the minus strand of HCV RNA on RNA synthesis directed by purified NS5B
ODN name Size
(mer)
Sequence (5 to 3) Position on the viral RNA
(indicated as 3–5)
IC50
(nM)
ODN1 17 TGATGGGGGCGACACTC 11–27 n.i
ODN2 26 AATCACTCCCCTGTGAGGAACTACTG 35–60 n.i
ODN3 20 CCTGGAGATTTGGGCGTGCC 218–237 1000
ODN4 14 GCGTTAGTATGAGT 88–101 n.i
ODN5 20 TCTAGCCATGGCGTTAGTAT 78–97 1000
ODN6 14 CCTTTCTTGGATAA 192–205 n.i
ODN7 19 ATGGCGTTAGTATGAGTGT 85–103 560
ODN8 20 GGTCCTTTCTTGGATAAACC 189–208 1000
ODN9 25 TGCCCCCGCAAGACTGCTAGCCGAG 234–258 800
ODN10 20 AAGACTGCTAGCCGAGTAGT 243–262 1000
ODN11 22 GGAACCGGTGAGTACACCGGAA 152–173 n.i
ODN12 21 ATGCCTGGAGATTTGGGCGTG 215–235 750
ODN13 20 CGCTCAATGCCTGGAGATTT 209–228 1000
Note. The upper part shows a diagram of the plus- and minus-strand of HCV RNA and the sequence corresponding to the 3-end of the minus strand. The
table indicates the size, sequence, and position of the ODNs targeted against the RNA. RdRp assays were performed as described under Materials and
Methods, using the 3-end (341 nt long) of the minus-strand RNA, named ()IRES, as template and different ODN concentrations. The RNA template was
preincubated with the ODN for 10 min at 25°C in 40 mM NaCl and then used in the RdRp assay. The IC50 is defined as the concentration of ODN leading
to 50% inhibition of RNA synthesis. n.i., no inhibition.
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Typical inhibition curves obtained with ODNs 3, 7, and
12 using ()IRES as template are shown in Fig. 1A. To
ascertain the sequence-specific, nature of the inhibition,
these ODNs were tested with another template, an RNA
fragment derived from the 3-end of the plus-strand RNA
that was noncomplementary to the ODNs. No inhibition of
RNA synthesis driven by ()3 UTR-N X was observed at
ODN concentrations that inhibited RNA synthesis directed
by ()IRES (Fig. 1A). It can therefore be hypothesized that
the lack of inhibition of these ODNs on RNA synthesis
directed by ()3 UTR-N X could be due to a higher
affinity of this RNA for NS5B as compared to that of
()IRES RNA. To address this point, gel shift experiments
were performed by incubating ()IRES or ()3 UTR-N
X RNAs with increasing amounts of NS5B. As shown in
Fig. 1B, the binding affinity of ()IRES RNA for NS5B
(lanes 2 to 6) was very similar to that of () 3 UTR-N X
RNA (lanes 8 to 12). Taken together, these data strongly
suggested that the inhibition of RNA synthesis by ODNs 3,
7, and 12 was due to the sequence-specific annealing of
these ODNs on ()IRES RNA rather than to their binding
to the template RNA-binding pocket of the enzyme.
The sequence-specific nature of this inhibition was fur-
ther confirmed by analyzing the 32P-labeled RNA products
on denaturing polyacrylamide gels. As we have previously
reported, two major RNA products are synthesized in vitro
by NS5B (Reigadas et al., 2001). Similar results were ob-
tained here as shown in Fig. 2. Using ()IRES (lane 1) and
()3 UTR-N X (lane 7) HCV RNA fragments as tem-
plates, two RNA products were obtained; a major band
Fig. 1. (A) Inhibition of RNA synthesis by ODN3, ODN7, and ODN12. RdRp assays were performed as described under Materials and Methods with RNA
templates preincubated in the presence or in the absence of different ODN concentrations. Two different templates were used as indicated: (empty circles)
the 3-end of the minus-strand RNA named ()IRES and (black squares) the 3-end of the plus-strand RNA containing the ()3 UTR-N X fragment. The
amount of RNA synthesized was determined by measuring the TCA-precipitable radioactivity in a scintillation counter. Results corresponding to mean values
of two independent experiments are expressed as relative activity, 100% corresponding to NS5B activity in the absence of ODN. (B) Gel shift of templates
RNA with NS5B. Labeled ()IRES RNA (10 000 cpm) (lanes 2 to 6) or ()3 UTR-N X RNAs (lanes 8 to 12) were incubated 10 min at 25°C in a 10-l
RdRp reaction mixture without NTP with increasing amounts of NS5B: no enzyme (lanes 1 and 7), 0.5 pmole (lanes 2 and 8), 1 pmole (lanes 3 and 9), 2
pmoles (lanes 4 and 10), 3 pmoles (lanes 5 and 11), 5 pmoles (lanes 6 and 12). The products were analyzed by electrophoresis on a 4% nondenaturing gel.
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corresponding to the full-length product and a minor band
of higher molecular weight produced by successive copies
of the template. This latter product is made up of two
covalently bound RNA molecules both complementary to
the template, whereas a copy-back product is composed of
a template molecule covalently bound to its complementary
RNA (Reigadas et al., 2001). As expected, in the presence
of ODN3, which is one of the inhibitory ODNs, the amount
of RNA products synthesized from the ()IRES template
decreased markedly (Fig. 2, lanes 2 to 6). In contrast, the
amount of RNA products synthesized from the ()3
UTR-N X template in the presence of ODN3 remained
constant (Fig. 2, lanes 8 to 12). Similar inhibition patterns
were obtained with ODN7 and ODN12 (data not shown).
Among the 13 ODNs analyzed, only 4 displayed an
inhibitory activity on RNA synthesis. The absence of an
inhibitory effect could be due to a lack of hybridization of
the ODN to the complementary sequence. To test this hy-
pothesis, we incubated ODNs 1, 3, 7, 11, and 12 to the
()IRES RNA and the corresponding hybrids were treated
with RNase H, an enzyme that specifically hydrolyzes the
RNA strand of RNA/DNA hybrids. The size of the expected
fragments obtained after RNase H digestion of the labeled
()IRES RNA hybridized to these ODNs is illustrated in
Fig. 3 A, B, and C (upper part). As shown in Fig. 3A, lane
1, when ()IRES RNA and ODN3 were incubated in the
absence of RNase H, an RNA band corresponding to the
size of the template (341 nt) was observed. After RNase H
treatment, this product disappeared almost completely to
give two major products of the expected sizes, 218 and 104
nt (lane 2). Two slower migrating faint bands were also
observed, possibly corresponding to incomplete RNase H
digestion products of the RNA/DNA hybrid (Wisniewski et
al., 2000). The presence of the 218- and the 104-nt bands
indicated that ODN3 is hybridized to its complementary
sequence present in the ()IRES RNA. Similar results were
obtained when labeled ()IRES hybridized to ODN7 or
ODN12 were treated with RNase H (Fig. 3B). After RNase
H digestion, the 341-nt RNA annealed to ODN7 was con-
verted into two major bands of the expected sizes, 85 and
238 nt (Fig. 3B, lane 2). Two major products of the expected
sizes (215 and 106 nt) were obtained when 32P-labeled RNA
hybridized to ODN12 was treated by RNase H (Fig. 3B,
lane 4).
In contrast, when RNase H was used to treat ()IRES
incubated with ODN1 or ODN11, two ODNs that did not
inhibit ()IRES-dependent RNA synthesis, we obtained no
digestion products with ODN1 and only very low amounts
with ODN11 (Fig. 3C). These data suggest that the absence
of inhibition of RNA synthesis by ODN1 and ODN11 was
related to a lack of hybridization or to the weak hybridiza-
tion of these two ODNs to the ()IRES template. The
binding of the 13 ODNs on ()IRES template was then
investigated by gel shift. All inhibitory ODNs were able to
bind to the template, whereas no binding was observed with
the noninhibitory ones. These results indicated that the
inhibitory activity of the ODNs was related to their binding
affinity for the RNA template. The only exception was
ODN2, which displayed no inhibitory activity even at 5
M, an ODN concentration where ()IRES RNA was al-
most completely shifted (data not shown).
Altogether, our results demonstrated that ODNs 3, 7, and
12 inhibited in vitro RNA synthesis from 3-end minus-
strand HCV RNA. This inhibition was related to their spe-
cific hybridization to the template.
Inhibition of in vitro RNA synthesis by 2-O-methyl ODNs
and phosphoramidate-modified ODNs
Several reports have shown that modifications of ODNs
can increase their affinity for the target RNA, their nuclease
resistance, and cellular uptake. We therefore introduced the
2-O-methyl modification (2-O-me) into ODNs 3, 7, and
12. As expected, the IC50 of 2-O-me ODN7 was lowered
11-fold after the chemical modification from 560 to 50 nM,
whereas, surprisingly, the IC50 values of ODN3 and ODN12
were not affected (Table 2). Inhibition by the modified
ODNs was sequence-specific because no effect by a random
2-O-me ODN was observed (Fig. 4A). Analysis of the
products synthesized by NS5B with the ()IRES region as
template in the presence of various concentrations of PO
ODN7 or 2-O-me ODN7 confirmed the inhibition (Fig. 4C
and D). The inhibition was stronger with 2-O-me ODN7
(lane 2 in Fig. 4C and lane 8 in Fig. 4D, where in each case
the synthesis was performed at an ODN concentration of
200 nM). When the phosphoramidate modification (PN)
was introduced into ODN7, the inhibition was even stronger
(IC50 30 nM) than with 2-O-me ODN7 (data not shown).
Fig. 2. Analysis of the RNA products synthesized by NS5B in the presence
or absence of ODN3. RNA templates were preincubated with the ODN for
10 min at 25°C in 40 mM NaCl and then used in RdRp assays. Reaction
products were denatured and loaded onto a 6% denaturing polyacrylamide
gel. Lanes 1 and 7 correspond to the complete reaction mixture, but without
the ODN. Antisense ODN3 was added as follows: 8 nM (lanes 2 and 8), 40
nM (lanes 3 and 9), 200 nM (lanes 4 and 10), 1 M (lanes 5 and 11), and
5 M (lanes 6 and 12). A labeled 0.16- to 1.77-kb RNA ladder (Gibco-
BRL) was used as size marker.
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Gel mobility shift assay of ()IRES RNA with PO or 2-
O-me ODNs
To determine the binding affinity of the ODNs for the
3-end of minus-strand HCV RNA, we performed gel mo-
bility shift assays with 32P-labeled ()IRES and various
concentrations of ODNs 3, 7, and 12 either modified or not.
Figures 4B and 5A shows the results with PO ODN7 and
2-O-me ODN7. The 2-O-me ODN7 presented higher af-
finity for the ()IRES RNA than the PO: A band corre-
sponding to the duplex was already observed at 10 mM
2-O-me ODN7 (Fig. 5A, lane 1), whereas a duplex ap-
peared at 100 nM PO ODN7 (Fig. 4B, lane 1). In contrast,
no RNA mobility shift was observed with a random 2-O-
methyl ODN (Fig. 4B, lanes 10–13), a sense ODN7 (data
not shown), or when the assay was performed with the
2-O-me ODN7 and 32P-labeled ()3 UTR-N X RNA
(Fig. 5B, lanes 1–6). A Kd value of 30 nM for 2-O-me
Table 2
IC50 and Kd values of PO and 2-O-methyl ODNs
PO 2-O-me
IC50(nM)
ODN3 1020 (90) 930 (50)
ODN7 560 (70) 50 (3)
ODN12 720 (50) 800 (30)
Kd(nM)
ODN3 180 (15) 180 (15)
ODN7 810 (10) 30 (5)
ODN12 340 (100) 260 (15)
Note. The IC50 values were determined in RdRp assays, including the
()IRES template preannealed with different concentrations of the com-
plementary PO or 2-O-me ODNs. Gel mobility shift assays were done in
the presence of labeled ()IRES RNA and ODNs, except for gel mobility
shift with ODN12 and 2-O-me ODN12 that were done in the presence of
labeled ODNs and ()IRES RNA. Data are expressed as means (
standard deviation) from at least three independent experiments.
Fig. 3. RNA digestion of RNA/DNA hybrids by HIV-1 and E. coli RNase H activities. (Upper part) Schematic representation of the expected RNA fragments
generated by RNase H. (A) Uniformly 32P-labeled ()IRES RNA (341 nt) preannealed with 1 M ODN3 (lanes 1 and 2) was incubated in the presence ()
or in the absence () of HIV-1 RT as described under Materials and Methods. (B) 32P-labeled ()IRES RNA preannealed with 1 M ODN7 (lanes 1 and
2) or 1 M ODN12 (lanes 3 and 4) was incubated in the presence () or in the absence () of E. coli RNase H. (C) 32P-labeled ()IRES RNA preannealed
with 1 M ODN1 (lanes 1 and 2) or 1 M ODN11 (lanes 3 and 4) was incubated in the presence () or in the absence () of E. coli RNase H. Reaction
products were denatured and loaded onto a 6% denaturing polyacrylamide gel. Similar results were obtained with E. coli or HIV-1 RNase H.
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ODN7 was determined by serial dilutions as illustrated in
Fig. 5A and C. Similarly, a Kd of 810 nM was obtained for
PO ODN7. Taken together, these results demonstrate that
the 2-O-me modification of ODN7 greatly enhances the
affinity of this ODN for its RNA target (Table 2). This
increased affinity is sequence-specific and correlates with
the higher inhibitory activity of modified ODN7 compared
to the unmodified one (Table 2).
Gel mobility shift of ()IRES RNA was also performed
with PO or 2-O-me ODN3 and ODN12. The Kd values of
PO ODN3 and ODN12 were 180 and 340 nM respectively
(Table 2). The chemical modification of these two ODNs
had no effect on either the affinity or the inhibitory activity,
possibly owing to particular structural features of the ODN
or the targeted region in the ()IRES RNA. It should be
noted that these two antisense ODNs are complementary to
sequences localized in overlapping regions of the viral RNA
(nt 218 to 237 for ODN3 and nt 215 to 235 for ODN12),
Fig. 4. Effect of PO and 2-O-methyl ODN7 on RNA synthesis with ()IRES as template. (A) The ()IRES RNA template was incubated for 1 h at 25°C
with NS5B after preincubation with various concentrations of PO-ODN7 (black squares), 2-O-methyl ODN7 (black triangles), or random 2-O-methyl ODN
(black circles). The amount of RNA synthesized was determined by measuring the TCA-precipitable radioactivity. (B). Gel mobility shift assays of labeled
()IRES with PO ODN7, 2-O-methyl ODN7, and random 2-O-methyl. 32P-labeled ()IRES RNA was incubated with ODNs and then loaded onto a 4%
polyacrylamide gel as described under Materials and Methods. Labeled ()IRES RNA alone (lane C) and plus PO ODN7 (lanes 1–5) at 100 nM, 200 nM,
500 nM, 1M, 5 M; 2-O-methyl ODN7 (lanes 6–9) or random 2-O-methyl ODN (lanes 10–13). The increasing amounts of ODNs used were the same in
the two latter cases: 200 nM, 600 nM, and 1 and 5 M. (C). RdRp reaction products were denatured as described under Materials and Methods and loaded
onto a 6% polyacrylamide gel. (Lane T) Uniformly 32P-labeled ()IRES template; (lane 1) complete reaction mixture in the absence of ODN; and (lanes
2–7) 200, 400, 600, 800 nM, and 1 and 5 M PO ODN7, respectively. (D) (Lane T) 32P-labeled ()IRES template; (lane 1) product synthesized without
ODN; (lanes 2–8) 10, 20, 40, 60, 80, 100, and 200 nM 2-O-methyl ODN7, respectively. A labeled 0.1- to 0.5-kb RNA ladder was used as size marker
(Ambion).
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whereas ODN7 is complementary to a sequence comprising
between nt 85 and 103.
Analysis of mechanisms of inhibition of RNA synthesis by
ODN7
The classical mechanism of nucleic acid biosynthesis
inhibition by antisense ODNs involves polymerization ar-
rest at the site at which the ODNs are annealed. In this case,
a short abortive RNA product should be visualized in de-
naturing polyacrylamide gels. However, no blockage band
was observed when RNA synthesis was performed in the
presence of PO ODN3 and ODN7 (Figs. 2 and 4C, respec-
tively) or PO ODN9 and ODN12 (data not shown). Nor was
any blockage band obtained with 2-O-me ODN7 (Fig. 4D)
or PN ODN7 (data not shown), even though these com-
pounds were stronger inhibitors than PO ODN7. This
clearly showed that the inhibitory ODNs did not interfere
with RNA synthesis by halting the elongation process at the
annealing site.
Other possible mechanisms of inhibition were further
investigated using ODN7, the most potent inhibitor. An
explanation of its effect could be that the hybridization of
ODN7 to viral RNA prevents the HCV RNA polymerase
from binding to the template. To address this issue, we
analyzed the interaction of viral RNA with the enzyme by a
filter-binding assay of the 32P-labeled ()IRES RNA with
the purified NS5B with or without ODN7. As shown in Fig.
6A, the enzyme retained 35% of the labeled RNA on the
filter. The same level of binding of the NS5B protein was
obtained when 32P-labeled ()IRES was prehybridized to
ODN7 or to 2-O-me ODN7, thereby suggesting that the
presence of ODNs on the RNA target did not prevent the
binding of NS5B to the 3-end fragment of minus-strand
HCV RNA.
An alternative mechanism to explain the inhibition could
be trapping of the HCV RNA polymerase by the RNA/ODN
duplex. To test this hypothesis, we determined the activity
of the polymerase using a second template, the ()3
UTR-N X RNA fragment, which is not complementary to
ODN7 (Fig. 6B). In contrast to the inhibition of the
()IRES-dependent RNA synthesis produced by 2-O-me
ODN7 when it is annealed to the ()IRES template (gray
bar), the RNA synthesis from the ()3 UTR-N X was
unaffected by the presence of either the 2-O-me ODN7
(hatched bars) or the duplex ()IRES RNA/2-O-me ODN7
(square bars). The control activity of HCV RNA polymerase
in the presence of the ()3 UTR-N X template is shown
by the white bars in Fig. 6B; as previously described (Reiga-
das et al., 2001) this template is less efficiently replicated
Fig. 5. Determination of the dissociation constant (Kd) of the duplex ()IRES/2-O-methyl ODN7. (A) Labeled ()IRES RNA alone (lane C) or (B) labeled
()3 UTR-N X RNA alone (lane C) with 10, 20, 40, 60, 80, and 100 nM 2-O-methyl ODN7 (lanes 1–6) were incubated as described in Fig. 4. (C) Double
inverted representation 1/duplex  f(1/ODN). Concentrations of 32P-labeled duplex and 32P-labeled ()IRES RNA were calculated as described under
Materials and Methods.
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than ()IRES. Since the ()3 UTR-N X was replicated
with the same efficiency in the presence of 2-O-me ODN7
or the duplex, the NS5B was not trapped by the duplex
()IRES/2-O-me ODN7.
Finally, we investigated whether ODN7 could displace
NS5B from ()IRES through a binding competition mech-
anism. For this, a gel retardation assay was performed by
incubating 32P-labeled ()IRES RNA with NS5B and in-
creasing amounts of 2-O-me ODN7. As shown in Fig. 7A,
lanes 3 to 7, the amount of RNA/NS5B complex did not
decrease in the presence of 2-O-me ODN7, even when
present at a concentration as high as 5 M. The same results
were obtained with ODN3 and ODN12 (data not shown).
On the contrary, unlabeled ()IRES RNA efficiently com-
peted against the fixation of the 32P-labeled RNA on NS5B
at 50 nM (Fig. 7B, lane 4). These results clearly indicate that
ODN3, -7, and -12 did not inhibit RNA synthesis by com-
peting with ()IRES RNA for binding to NS5B.
ODN7 interferes with initiation
We have previously shown that when an RNA corre-
sponding to the 341 nt of the 3-end of the minus-strand
HVC RNA is used as template by NS5B, initiation occurs
by a de novo mechanism at the 3-end (Reigadas et al.,
2001). In the secondary structure of this viral RNA fragment
as determined by Schuster et al. (2002) and Smith et al.
(2002), the complementary sequence of ODN7 is located at
the bottom of a long stem-loop (SLB1) near the 3-end of
the RNA (Fig. 8).
The inhibition produced by ODN7 might be due to its
hybridization preventing the correct folding of the RNA
required for efficient initiation. To test this hypothesis, we
preformed the ()IRES/NS5B complex prior to adding the
ODN. In all the assays reported above, the ODNs were
preincubated with the ()IRES template before adding the
enzyme. In this experiment, NS5B was preincubated for 10
min at 25°C with the ()IRES template in the RdRp reac-
tion mixture without NTP or with 0.5 mM GTP and CTP.
Different dilutions of the ODN7 were then added and incu-
bated for 10 min at 25°C. The polymerization reaction was
started by adding 32P-labeled -UTP and the 3-unlabeled
NTP or 32P-labeled -UTP and unlabeled ATP, respec-
tively. Incubation was continued for 15 min at 25°C. GTP
and CTP were used because they are the two initiating
nucleotides on the 3-end of the HCV minus-strand RNA.
Consequently, at the time when ODN7 was added, an ini-
tiation complex had already formed.
As shown in Fig. 9A, when NS5B was preincubated with
the ()IRES template without NTP before the addition of
ODN7 (curve with black squares), a strong inhibition of
RNA synthesis was observed, identical to that obtained
when ODN7 was preincubated with the template (Fig. 1).
On the contrary, when NS5B was preincubated with the
()IRES template in the presence of GTP and CTP, thus
allowing the formation of the initiation complex, the inhi-
bition of ODN7 was significantly reduced (Fig. 9A, curve
with empty squares). It was recently shown that NS5B
possesses a specific GTP binding site on the molecular
surface at the interface between fingers and thumb, 30 Å
away from the catalytic site. The biological significance of
this additional GTP site is unknown, although it has been
suggested that it might play a role in allowing alternative
interactions between the two domains during a conforma-
tional change of the enzyme required for efficient initiation
(Bressanelli et al., 2002). We investigated whether inhibi-
tion by ODN7 was also reduced when NS5B and the
()IRES template were preincubated with GTP alone. As
shown in Fig. 9A (curve with empty triangles), the level of
inhibition was identical to that obtained when NS5B and the
template were preincubated in the absence of NTP, thus
indicating that preincubation with GTP alone did not affect
inhibition of RNA synthesis by ODN7. To confirm that the
decrease in ODN7 inhibition was dependent of the presence
of the two initiating nucleotides (CTP and GTP) prior to the
Fig. 6. Binding assays and effect of the duplex RNA/ODN on RNA
synthesis by NS5B in vitro. (A) The binding reactions were performed as
described under Materials and Methods in the presence of uniformly
radiolabeled ()IRES. NS5B was incubated with ()IRES alone (black
bars), the duplex ()IRES/PO ODN7 (hatched bars), or the duplex
()IRES/2-O-methyl ODN7 (squared bars). Results are expressed as the
percentage of binding of the ()IRES template to the NS5B; 100% cor-
responds to the amount of 32P-labeled ()IRES RNA template. Results
correspond to mean values of two independent experiments. (B) RdRp was
incubated in the presence of different templates and ODNs as described in
the text and indicated in the figure. RNA synthesis in the presence of
()IRES template (black bars), ()IRES template and 100 nM 2-O-methyl
ODN7 (grey bars), ()3 UTR-N X template alone (white bar), ()3
UTR-N X template in the presence of 100 nM 2-O-methyl ODN7
(hatched bars), ()3 UTR-N X template and the duplex ()IRES/2-O-
methyl ODN7 (squared bars). Results correspond to mean values of two
independent experiments.
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addition of AS-ODN, NS5B and the ()IRES template
were preincubated with GTP and ATP, which could be
incorporated at the 4 position in the newly synthesized
RNA. Under these conditions, RNA synthesis was strongly
inhibited by ODN7, like when the NS5B/RNA complex was
allowed to form without NTP (data not shown).
Altogether, these results indicated that when RNA syn-
thesis was already initiated in the presence of NS5B,
()IRES RNA, and the two initiating nucleotides (GTP and
CTP), the inhibitory effect of ODN7 was greatly reduced.
This strongly suggested that ODN7 inhibited RNA synthe-
sis by preventing its initiation. It is tempting to postulate
that the annealing of ODN7 alters the structure of the RNA
template in a domain important for efficient initiation from
the HCV 3-end RNA. The residual inhibitory activity of
ODN7 is most probably due to the experimental conditions
where re-initiation events may occur.
It could be argued that the low degree of inhibition
observed when NS5B and the template were pre-incu-
bated with GTP and CTP was due to the synthesis of long
RNA products encompassing the ODN7 hybridization
site by mis-incorporation during the pre-incubation pe-
riod, even though the reaction was performed with Mg2
as divalent cation. To rule out this possibility, RNA
synthesis with ()IRES template was performed for 20
min in the presence of 0.5 mM GTP, 32P-labeled -CTP
and the products were analyzed on a denaturing 12%
polyacrylamide gel. As shown in Fig. 9B (lane 1), in the
presence of only CTP and GTP, a ladder of RNA prod-
ucts shorter than 35 nt was synthesized. These products
stopped far before the hybridization site of the ODN7 (nt
85–103 from the 3-end) and could not be the cause of the
lower inhibition of RNA synthesis after preincubation
with CTP and GTP. When the same experiment was
performed in the presence of 5 M ODN7, the synthesis
of the short initiation products was almost completely
inhibited (Fig. 9B, lane 2), whereas it was only partially
reduced in the presence of ODN3 or ODN12 (Fig. 9B,
lanes 3 and 4). These results clearly demonstrated that
ODN7 inhibited the initiation step of RNA synthesis
from the ()IRES RNA. The ODN3 and ODN12 also
decreased the level of RNA initiation but to a lesser
extent compared to ODN7. Further experiments are
needed to determine whether this is due to their lower
inhibitory activity or if they have no direct effect on
initiation.
Fig. 7. Competition gel shift assay between 32P-labeled ()IRES RNA and 2-Ome ODN7 or ()IRES RNA. (A) NS5B (3 pmoles) was incubated in 10 l
RdRp reaction mixture with 10 000 cpm 32P-labeled ()IRES RNA and increasing amounts of 2-O-me ODN7 (10 nM, 50 nM, 100 nM, 200 nM, 500 nM,
and 1 M) (lanes 3 to 7). (B) NS5B (5 pmoles) was incubated in 10 l RdRp reaction mixture with 10 000 cpm 32P-labeled ()IRES RNA and increasing
amounts of unlabeled ()IRES RNA (10 nM, 50 nM, 200 nM, and 800 nM) (lanes 3 to 6). (Lane 1) No NS5B; (lane 2) No RNA, plus NS5B.
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Discussion
In this study we describe antisense ODNs that are able to
strongly inhibit RNA synthesis driven from the 3-end of
HCV minus-strand RNA by the purified HCV RdRp. These
ODNs are complementary to two domains of the HCV
minus-strand RNA, a region comprising between nt 85 and
103 and another from nt 215 to 258.
Four PO ODNs were able to inhibit RNA synthesis with
an IC50 1 M. The effect was sequence-specific, since no
inhibition of the enzyme activity was observed when these
ODNs were used with a noncomplementary template,
thereby ruling out a direct inhibition of the enzyme.
To increase the affinity for the RNA target, we intro-
duced a 2-O-methyl modification into ODNs 3, 7, and 12;
the best PO ODN inhibitors; and a PN modification into
ODN7. Chemical modifications enhanced the affinity of
ODN7 (Table 2) but did not affect that of ODN3 or ODN12.
Similarly, the inhibition of RNA synthesis by 2-O-me and
PN ODN7 was highly increased when compared to its PO
counterpart, whereas no changes were observed for ODNs 3
and 12. All these results point to the importance of the
structure and/or the sequence of the viral RNA target and
the antisense ODNs.
Further characterization of the antisense-mediated inhi-
bition led us to analyze the RNA products synthesized by
NS5B in the presence of ODNs. Under none of our exper-
imental conditions did we observe the expected short prod-
uct corresponding to a stop of the polymerase at the anti-
sense annealing site. This result strongly suggested that the
antisense molecules did not inhibit RNA synthesis by inter-
fering with the elongation process. Additional experiments
performed with the ODN7, the most potent inhibitor, indi-
cated that this effect was due neither to the competitive
Fig. 8. Secondary structure of the 3-end of the HCV-minus-strand RNA (adapted from Schuster et. al, 2002). The dotted lines show the viral RNA sequence
complementary to ODNs.
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annealing of ODN7 at the binding site of the NS5B on the
()IRES RNA nor to an inactivation of the NS5B by
trapping on the template/ODN7 hybrid. Nor was it due to
competition for the template binding pocket of the viral
polymerase. In view of these data, it could be hypothesized
that ODN7 inhibited RNA synthesis by affecting important
structural features of viral RNA regions involved in the
efficient initiation of RNA synthesis by HCV NS5B.
This hypothesis is supported by our results showing that
the inhibition of RNA synthesis by ODN7 was greatly
reduced when a polymerase/template complex was formed
in the presence of the two initiating nucleotides GTP and
CTP to synthesize the beginning of the plus-strand RNA
(GCCAGCCCCC). In contrast, the inhibition was not af-
fected when the complex was formed in the absence of
NTP, in the presence of GTP and ATP, or in that of GTP
alone. A definitive proof demonstrating that ODN7 inhib-
ited the initiation of the RNA synthesis from the ()IRES
template was provided by the experiment in Fig. 9B show-
ing that ODN7 prevented the synthesis of the short initiation
products synthesized in the presence of CTP and GTP. Our
results are in accordance with those of Shim et al. (2002),
who demonstrated that de novo RNA synthesis by NS5B
starts with the formation of an initiation product, a dinucle-
otide, from the first nucleotidyl transfer reaction.
Our data strongly suggest that the region of the 3-end of
the HCV minus-strand RNA that is complementary to
ODN7 is involved in the actual first step in RNA synthesis
or a step very soon after incorporation of first nucleotides in
the RNA product. When ODN7 was hybridized to this
sequence, it may inhibit the formation of the initiation
complex or induce structural rearrangement of the protein–
RNA complex. Further experiments are in progress to de-
termine the effect of ODN7 on whole HCV minus-strand
RNA both in vitro using recombinant NS5B and ex vivo in
the replicon cell culture system (Lohmann et al., 1999).
Antisense agents may prove to be very useful as tools
both for studying the mechanism of viral nucleic acid syn-
thesis and in the search for new potentially therapeutic
compounds. Data suggesting that antisense ODNs inhibit
the initiation of RNA synthesis by interfering with RNA
folding have been previously reported in the case of rota-
viruses. Patton et al. (1996) and Wentz et al. (1996) showed
that deletion of the 3-conserved sequence UGUGACC pre-
vents rotavirus mRNA from serving as template for minus-
strand RNA synthesis. Using antisense ODNs, Barro et al.
(2001) showed that ODNs annealed more than 15 nt up-
stream of the last six residues of the 3-end of the RNA were
able to inhibit RNA synthesis. As in our case, no short RNA
bands were observed, thus suggesting that antisense ODNs
do not inhibit replication by interfering with the elongation
of the minus-strand RNA. Rather, their data suggest that
sequences outside the 3-conserved region influence the
efficiency of the initiation of RNA synthesis.
Moreover, two groups have recently demonstrated that
sequences in the 5 nontranslated region of the HCV ge-
nome are required for RNA replication in a replicon cell
culture system. It was shown that the 125 5-terminal nu-
cleotides of the HCV genome are sufficient for RNA rep-
lication. The 3-border of the minimum replication signal
was mapped between nt 84 and 125 (Friebe et al., 2001;
Kim et al., 2002). It should be noted that ODN 7 is annealed
Fig. 9. Inhibition of RNA synthesis by ODN7 in the presence of the 4 NTP or of CTP and GTP. (A) NS5B was preincubated 10 min at 25°C with the ()IRES
template in the RdRp reaction mixture without NTP (black squares) or with 0.5 mM GTP and CTP (empty squares) or 0.5 mM GTP (empty triangles). The
ODN7 was then added at 100 nM, 200 nM, 500 nM, 1 M, and 5 M and incubated 10 min at 25°C and the reaction of polymerization started by adding
32P-labeled UTP and 0.5 mM of the 3-unlabeled NTP (black squares), or 0.5 mM unlabeled ATP (empty squares), or 0.5 mM of ATP and CTP (empty
triangles). The incubation was continued for 15 min at 25°C. The amount of RNA synthesized was determined by measuring the TCA-precipitable
radioactivity in a scintillation counter. Results are expressed as relative activity, 100% corresponding to NS5B activity in the absence of ODN. Each point
corresponds to the mean ( SD) of three independent experiments. (B) RNA synthesis catalyzed by NS5B from ()IRES template was performed for 20
min in the presence of 2 M 32P-labeled -CTP and 0.5 mM GTP without ODN (lane 1), with 5 M ODN7 (lane 2), with 5 M ODN3 (lane 3), or with
5 M ODN12 (lane 4). Reaction products were denatured and loaded onto a 12% denaturing polyacrylamide gel.
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to a sequence complementary to nt 85 to 103, a region
which is part of the minimum replication signal identified
by Friebe et al. (2001). Although the role of the region
between nt 84 and 125 in the HCV replication is still
unknown, its complementary region could be part of se-
quences or structures important for the synthesis of positive-
sense RNA from negative-sense RNA. This hypothesis is in
agreement with the results of Kashiwagi et al. (2002) who
demonstrated that deletion of the region of the HCV minus-
strand RNA comprised between nt 42 and 118 from the
3-end of the minus-strand RNA markedly reduced the level
of RNA synthesis catalyzed in vitro by NS5B.
In conclusion, we present the first evidence of the in vitro
inhibition of HCV RNA synthesis by antisense ODNs. The
approach used in this study may help to identify sequences
in the viral genome playing a key role in HCV replication
and lead to designing new inhibitors with therapeutic po-
tential against HCV infection.
Materials and methods
Materials
Proteins
The recombinant HCV NS5B was expressed in Esche-
richia coli and purified as previously described (Reigadas et
al., 2001). HIV-1 reverse transcriptase was expressed in
yeast cells and purified as previously described (Sal-
lafranque-Andreola et al., 1989). E. coli RNase H was from
GIBCO-BRL Life Technologies, Inc.
Oligodeoxynucleotides
Nucleotide sequence from the HCV H77C strain was
used to design all the antisense ODNs (Yanagi et al., 1997).
Phosphodiester ODNs were purchased from MWG Biotech.
Methods
In vitro transcription
RNA fragments corresponding to the 3-end of plus- and
minus-strand RNA of HCV were synthesized by in vitro
transcription of DNA obtained by PCR amplification from
the pCV-H77 molecular clone (Yanagi et al., 1997) kindly
provided by Dr. Jens Bukh (Laboratory of Infectious Dis-
eases, NIH, Bethesda, USA). The polymerase chain reaction
(PCR) primers were designed to introduce a T7 RNA poly-
merase promoter in the correct orientation. The primers
used for the synthesis of the 3-end of the minus-strand
RNA [called ()IRES] template were 5 TAATACGACT-
CACTATAGGGTGCACGGTCTACGAGACCT 3 and 5
GCCAGCCCCCTGATGGGGGCGA 3 and those used for
the synthesis of the 3-end of the plus-strand RNA (called:
()3 UTR-N X) were 5 AAATAATACGACTCAC-
TATAGCCGGCTGGACTTGTCCGG 3 and 5 GGAGC-
CACCATTAAAGAAGGG 3 (the T7 promoter sequence is
underlined). PCR was performed with the AmpliTaq gold
DNA polymerase kit (Perkin–Elmer). RNAs were synthe-
sized using the MEGAscript kit (Ambion). DNA templates
were digested with DNase for 15 min. After phenol/chlo-
roform extraction, the RNAs were precipitated with isopro-
panol. The purity and the integrity of RNAs were deter-
mined by analysis on a 6% polyacrylamide gel containing 7
M urea in TBE buffer (90 mM Tris–borate, pH 8.0, 1 mM
EDTA).
RNA and ODN labeling
RNAs were labeled by in vitro transcription using the
MEGAscript kit and 15 Ci 32P-labeled -UTP (Amersham
Pharmacia Biotech). ODNs (10 pmol) were labeled with 50
Ci 32P-labeled -ATP (3000 Ci/mmol) and T4 polynucle-
otidyl kinase by incubation in a total volume of 10 l for 30
min at 37°C, according to the manufacturer’s instructions
(Promega). The amount of radioactivity incorporated into
the nucleic acids was measured by precipitating 2-l ali-
quots with 10% trichloracetic acid (TCA) and counting in a
Wallac scintillation counter. RNA and ODNs were precip-
itated with isopropanol and butanol respectively and dis-
solved in water.
Purification of ODNs
ODNs were analyzed by electrophoresis on a 15% poly-
acrylamide gel containing 7 M urea in TBE buffer. The gel
fragment containing the ODN was excised and incubated
for 1 h at 40°C in 10 mM Tris (pH 7.4), 25 mM NaCl, 1 mM
EDTA. Incubation was continued overnight at room tem-
perature under stirring. Acrylamide was eliminated on a
Centrex MF disposable microfilter (Schleicher & Schuell).
Salts were removed using a Sephadex G10 spin column and
ODNs were precipitated with butanol.
In vitro RdRp assay
The assay was performed in a total volume of 25 l
containing 20 mM Tris–HCl (pH 7.5), 1 mM DTT, 5 mM
MgCl2, 40 mM NaCl, 17 U RNasin (Promega), 0.5 mM
each of the 3 NTP (ATP,CTP,GTP), 2.15 pmol of RNA
template, 3.75 pmol of purified NS5B, and either 12.5 Ci
32P-labeled -UTP (3000 Ci/mmol, Amersham Pharmacia
Biotech) or 2 M UTP or 2 Ci [32H]UTP (46 Ci/mmol).
The reaction mixture was incubated for 1–2 h at 25°C and
stopped by the addition of 10% TCA. The radioactivity
incorporated into newly synthesized RNA was then deter-
mined. To analyze the 32P-labeled RNA, the synthesis was
stopped by adding 6.25 mM EDTA, 10 mM Tris–HCl (pH
7.5), and 0.125% SDS followed by a phenol/chloroform
extraction (1/1 vol/vol). RNAs were precipitated by 1 vol of
isopropanol in the presence of 0.5 M ammonium acetate.
RNAs were dissolved in 95% formamide, 0.5 mM EDTA,
0.025% SDS, 0.025% bromophenol blue, 0.025% xylene
cyanol and then heated for 2 min at 94°C and loaded onto
a 6% polyacrylamide denaturing gel containing 7 M urea in
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TBE buffer. After electrophoresis the gel was dried and
autoradiographied using Kodak Xomat-AR-5 films.
Inhibition experiments
The RNA templates and the antisense ODNs were first
prehybridized for 10 min at 25°C in 40 mM NaCl and then
added to the complete reaction mixture of the RdRp assay.
In experiments where the RdRp/RNA complex was al-
lowed to form before addition of antisense ODN, the en-
zyme and the RNA template were preincubated for 10 min
at 25°C in the RdRp reaction mixture without NTP or with
0.5 mM of the indicated NTP(s). Antisense ODN was then
added and incubated for 10 min at 25°C. The polymeriza-
tion reaction was started by adding 10 Ci of 32P-labeled
-UTP (2 M) and 0.5 mM unlabeled ATP, CTP, and GTP,
when not added during preincubation. Incubation was per-
formed for 15 min at 25°C.
RNase H assay
RNase H assay was performed in a total volume of 25 l
containing 50 mM Tris–HCl (pH 8.0), 6 mM MgCl2, 20
mM NaCl, 2 mM DTT, 60 mM KCl, 2 pmol of a duplex
containing labeled RNA (50 000 cpm/l) and different
ODNs, and 900 nM of HIV-1 RT or 2 U of E. coli RNase
H. RNA template and antisense ODNs were prehybridized
for 10 min at 25°C in a buffer containing 20 mM NaCl.
Incubation proceeded for 1 h at 37°C. The reaction products
were analyzed on 6% polyacrylamide-TBE-7M urea dena-
turing gels as described above.
Filter binding assay
Radiolabeled RNA template (650 fmol; 50,000 cpm) was
preincubated with 2 pmol of ODN in 20 mM Tris (pH 7.5),
1 mM DTT, 100 mM NaCl, 17 U RNasin (Promega), 5 mM
MgCl2 for 10 min at 25°C, in a total volume of 20 l. HCV
RNA polymerase (3.75 pmol) was then added and incuba-
tion proceeded for 20 min at 25°C. The mixture was filtered
through an MF membrane filter (Millipore). Filters were
washed three times with 20 mM Tris (pH 7.5), 100 mM
NaCl, and 5 mM MgCl2. The radioactivity retained on the
filter was determined by scintillation counting.
Gel mobility shift assay
Labeled RNA (130 fmol) was incubated in 10 l RdRp
reaction mixture with different ODN or enzyme concentra-
tions for 10 min at 25°C. Incubation was stopped by addi-
tion of 2 l of electrophoresis loading buffer [10 mM Tris
(pH 8.0), 1 mM EDTA, 0.1% bromphenol blue, 0.1% xy-
lene cyanol, 30% glycerol]. Samples were then loaded onto
a nondenaturing 4% polyacrylamide gel (acrylamide:bis
acrylamide 59/1) and run at 200 V for 6 h at room temper-
ature. The gel was autoradiographed and scanned using the
NIH Image program. The Kd was calculated by using a
double inverted representation according to the following
equation:
1/[ODN  RNA] Kd/[ODN][RNA],
where [ODNRNA] is the concentration of the complex.
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